Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 4:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–46 of 22 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Critical Limb Ischemia (CLI) Clear all
Completed Not applicable Interventional

Study of Autologous Bone Marrow Concentrate for the Treatment of Critical Limb Ischemia (CLI)

NCT00498069
View directory record Official record
Conditions
Ischemia
Interventions
Harvest Smartprep2 BMAC System, SmartPReP2 BMAC System, placebo
Device · Biological
Lead sponsor
Harvest Technologies
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
6
States / cities
Tampa, Florida • Boston, Massachusetts • Albany, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2015 · Synced Jun 10, 2026, 4:37 PM EDT
Completed No phase listed Observational

SCOPE CLI (Shifting Care and Outcomes for Patients With Endangered Limbs - Critical Limb Ischemia)

NCT03171259
View directory record Official record
Conditions
Critical Limb Ischemia
Interventions
care as usual
Other
Lead sponsor
Saint Luke's Health System
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
2
States / cities
New Haven, Connecticut • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 23, 2024 · Synced Jun 10, 2026, 4:37 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

BGC101 (EnEPC) Autologous Cell Therapy From Patient's Own Blood for Treatment of Critical Limb Ischemia (CLI)

NCT02805023
View directory record Official record
Conditions
Chronic Limb-Threatening Ischemia, Peripheral Arterial Disease, Peripheral Vascular Disease
Interventions
BGC101 (autologous EnEPC preparation), Control medium
Biological
Lead sponsor
BioGenCell Ltd.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
3
States / cities
San Francisco, California • New Haven, Connecticut • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 5, 2025 · Synced Jun 10, 2026, 4:37 PM EDT
Completed Phase 2 Interventional Results available

A Phase IIB Pilot Study of a Modified Dosage Regimen of AMG0001 in Subjects With Critical Limb Ischemia

NCT02016755
View directory record Official record
Conditions
Critical Limb Ischemia, Vascular Diseases, Peripheral Arterial Disease
Interventions
HGF Plasmid
Biological
Lead sponsor
AnGes USA, Inc.
Industry
Eligibility
40 Years to 90 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Jan 21, 2021 · Synced Jun 10, 2026, 4:37 PM EDT
Completed Phase 3 Interventional

An Efficacy and Safety Study of Ixmyelocel-T in Patients With Critical Limb Ischemia (CLI)

NCT01483898
View directory record Official record
Conditions
Critical Limb Ischemia
Interventions
Ixmyelocel-T, Placebo
Biological · Other
Lead sponsor
Vericel Corporation
Industry
Eligibility
35 Years to 90 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
86
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 63 more
Source: ClinicalTrials.gov public record
Updated May 26, 2021 · Synced Jun 10, 2026, 4:37 PM EDT
No Longer Available No phase listed Expanded access

Expanded Access Treatment of Subjects With Critical Limb Ischemia (CLI) With Minor Tissue Loss Who Are Unsuitable for Revascularization

NCT03886506
View directory record Official record
Conditions
Critical Limb Ischemia (CLI)
Interventions
PLX-PAD
Biological
Lead sponsor
Pluristem Ltd.
Industry
Eligibility
45 Years to 99 Years
U.S. locations
2
States / cities
Clifton, New Jersey • Teaneck, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Jun 10, 2026, 4:37 PM EDT
Not listed Phase 4 Interventional

Effect of Evolocumab in Patients With Critical Limb Ischemia (Evol-CLI)

NCT04306471
View directory record Official record
Conditions
Critical Limb Ischemia
Interventions
Evolocumab 140mg/mL Injector 1milliliter (mL) Pen x 3 for a monthly dose of 420 mg for 12 months., Placebo 1 milliliter (mL) Injector Pen x 3 monthly for 12 months
Drug · Other
Lead sponsor
Leonardo Clavijo
Other
Eligibility
40 Years to 85 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 12, 2020 · Synced Jun 10, 2026, 4:37 PM EDT
Withdrawn Not applicable Interventional

Correlation Between FlowMet™ and Other Gold Standard Assessments in the Management of Critical Limb Ischemia (CLI)

NCT03094559
View directory record Official record
Conditions
Critical Limb Ischemia
Interventions
FlowMet
Device
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 12, 2017 · Synced Jun 10, 2026, 4:37 PM EDT
Completed Not applicable Interventional

BOLD MRI as a Surrogate of Improved Muscle Oxygenation Following Endovascular Therapy for the Treatment of CLI

NCT02601430
View directory record Official record
Conditions
Peripheral Arterial Disease, Critical Limb Ischemia
Interventions
BOLD-MRI
Other
Lead sponsor
Zimmer Biomet
Industry
Eligibility
19 Years to 89 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Springfield, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 11, 2017 · Synced Jun 10, 2026, 4:37 PM EDT
Terminated Phase 3 Interventional

Efficacy/Safety of Ecraprost in Lipid Emulsion for Treatment of Critical Leg Ischemia Due to Peripheral Arterial Disease

NCT00059644
View directory record Official record
Conditions
Peripheral Vascular Disease
Interventions
Ecraprost in lipid emulsion
Drug
Lead sponsor
Tanabe Pharma Corporation
Industry
Eligibility
40 Years and older
Enrollment
560 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
20
States / cities
Phoenix, Arizona • Tucson, Arizona • Glendale, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jun 10, 2026, 4:37 PM EDT
Completed Phase 1 Interventional

Safety Study of Bone Marrow Cell Concentrate Prepared Using the Magellan System to Treat Critical Limb Ischemia (CLI)

NCT01386216
View directory record Official record
Conditions
Critical Limb Ischemia (CLI), Peripheral Vascular Disease (PVD)
Interventions
Magellan®
Device
Lead sponsor
Arteriocyte, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 23, 2017 · Synced Jun 10, 2026, 4:37 PM EDT
Completed Phase 2 Interventional

Study to Evaluate the Safety and Efficacy of JVS-100 Administered to Adults With Critical Limb Ischemia

NCT01410331
View directory record Official record
Conditions
Critical Limb Ischemia
Interventions
JVS-100(4 mg) or placebo/8 injections, JVS-100(8 mg) or placebo/8 injections, JVS-100(8 mg) or placebo/16 injections, JVS-100(16 mg) or placebo/16 injections
Biological
Lead sponsor
Juventas Therapeutics, Inc.
Industry
Eligibility
40 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
5
States / cities
Birmingham, Alabama • Chicago, Illinois • Minneapolis, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2014 · Synced Jun 10, 2026, 4:37 PM EDT
Terminated Phase 3 Interventional

Study of Remodulin in Patients With Critical Limb Ischemia With No Planned Revascularization Procedures

NCT00060996
View directory record Official record
Conditions
Critical Limb Ischemia, Peripheral Vascular Disease, Foot Ulcers, Rest Leg Pain
Interventions
Remodulin® (treprostinil sodium) Injection
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
7
States / cities
Tampa, Florida • Worcester, Massachusetts • Minneapolis, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2013 · Synced Jun 10, 2026, 4:37 PM EDT
Completed Phase 2 Interventional

Study to Assess Efficacy and Safety of Bone Marrow Derived Stem Cells in Patients With Critical Limb Ischemia

NCT01867190
View directory record Official record
Conditions
Critical Limb Ischemia
Interventions
ASCT01 (Autologous Stem Cell Transplantation)
Biological
Lead sponsor
Lifecells, LLC.
Industry
Eligibility
18 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
North Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 21, 2019 · Synced Jun 10, 2026, 4:37 PM EDT
Completed Phase 3 Interventional

Bone Marrow Aspirate Concentrate (BMAC) for Treatment of Critical Limb Ischemia (CLI)

NCT01245335
View directory record Official record
Conditions
Critical Limb Ischemia
Interventions
BMAC injection, Placebo injection
Device
Lead sponsor
Harvest Technologies
Industry
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
34
States / cities
Birmingham, Alabama • El Dorado, Arkansas • Los Angeles, California + 30 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2015 · Synced Jun 10, 2026, 4:37 PM EDT
Recruiting Not applicable Interventional

Ultrasound Cavitation Therapy for CLI

NCT05749250
View directory record Official record
Conditions
Peripheral Arterial Disease
Interventions
Acoustic cavitation of ultrasound enhancing agents
Device
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 28, 2023 · Synced Jun 10, 2026, 4:37 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Feasibility Study to Evaluate Therapeutic Ultrasound (TUS) to Acutely Increase the Perfusion in Peripheral Arterial Disease (PAD)

NCT05888740
View directory record Official record
Conditions
Peripheral Arterial Disease
Interventions
VibratoSleeve Therapeutic Ultrasound Device
Device
Lead sponsor
Vibrato Medical, Inc.
Industry
Eligibility
65 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Jul 1, 2025 · Synced Jun 10, 2026, 4:37 PM EDT
Not listed Not applicable Interventional Results available

PROMISE II: Percutaneous Deep Vein Arterialization for the Treatment of Late-Stage Chronic Limb-Threatening Ischemia

NCT03970538
View directory record Official record
Conditions
Critical Limb Ischemia, Critical Lower Limb Ischemia, Peripheral Artery Disease, Peripheral Arterial Disease, Chronic Limb-Threatening Ischemia, Arterial Occlusive Diseases, Arterial Occlusion, Arterial Disease, Peripheral Artery Occlusion, Peripheral Vascular Disease, Peripheral Ischemia, Vascular Diseases
Interventions
LimFlow System
Device
Lead sponsor
LimFlow, Inc.
Industry
Eligibility
18 Years to 95 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
20
States / cities
San Francisco, California • Torrance, California • New Haven, Connecticut + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2024 · Synced Jun 10, 2026, 4:37 PM EDT
Active, not recruiting Not applicable Interventional Results available

LIFE-BTK PK Sub-study

NCT05208905
View directory record Official record
Conditions
Critical Limb Ischemia (CLI)
Interventions
Esprit BTK Device
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
3
States / cities
Jacksonville, Florida • South Dartmouth, Massachusetts • Bartlesville, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jan 25, 2026 · Synced Jun 10, 2026, 4:37 PM EDT
Active, not recruiting No phase listed Observational

SCOPE-CLI: Shifting Care and Outcomes for Patients With Endangered Limbs

NCT04710563
View directory record Official record
Conditions
Peripheral Arterial Disease
Interventions
Not listed
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
458 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 19, 2025 · Synced Jun 10, 2026, 4:37 PM EDT
Completed Phase 1Phase 2 Interventional

Injection of Autologous CD34-Positive Cells for Critical Limb Ischemia

NCT00616980
View directory record Official record
Conditions
Peripheral Artery Disease, Peripheral Vascular Disease, Critical Limb Ischemia
Interventions
CD34-positive cells, Saline and 5% autologous plasma
Biological
Lead sponsor
Losordo, Douglas, M.D.
Individual
Eligibility
21 Years to 80 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
12
States / cities
Birmingham, Alabama • Gainsville, Florida • Orlando, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2011 · Synced Jun 10, 2026, 4:37 PM EDT
Completed Phase 2 Interventional Results available

ACP-01 in Patients With Critical Limb Ischemia

NCT02551679
View directory record Official record
Conditions
Critical Limb Ischemia
Interventions
ACP-01, Placebo
Biological
Lead sponsor
Hemostemix
Industry
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
16
States / cities
Sacramento, California • Aurora, Colorado • Gainesville, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 27, 2023 · Synced Jun 10, 2026, 4:37 PM EDT